Public Company List
| Ticker | Company | Lead Asset | Indication | Stage | Next Catalyst |
|---|---|---|---|---|---|
| BCDA | BioCardia Inc | Autologous cell therapy | Heart Failure, Systolic | Phase 3 | 2026-12 |
| CELZ | Creative Medical Technology Holdings Inc | Infusion | n/a | n/a | 2027-01-31 |
| SNSE | Sensei Biotherapeutics Inc | SNS-301 | Squamous Cell Carcinoma of the Head and Neck | Phase 2 | 2027-06 |
| CLRB | Cellectar Biosciences Inc | NOV-205 | Hepatitis C | Phase 2 | 2028-02 |
| CRIS | Curis Inc | CUDC-907 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | Phase 2 | 2028-07-31 |
| BCAB | BioAtla Inc | CAB-AXL-ADC | Non-Small-Cell Lung Cancer | Phase 2 | 2028-09-15 |
| HYFT | MindWalk Holdings Corp | All-in-one biointelligence ecosystem | therapeutic and anti-drug antibodies, diagnostics, vaccines, and peptide therapeutics | n/a | n/a |
| KAPA | Kairos Pharma Ltd | ENV105 | Phase II Prostate Cancer Trial and for Phase I Non-Small Cell Lung Cancer for ENV105 | Approved | n/a |
| SNTI | Senti Biosciences Holdings Inc | SENTI-202 | n/a | Phase 1 | n/a |
| TVGN | Tevogen Bio Holdings Inc | TVGN-489 | n/a | Preclinical | n/a |
| TVRD | Tvardi Therapeutics Inc | TTI-101 | Head and Neck Squamous Cell Carcinoma | Approved | n/a |